Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
Research Triangle Park Foundation · GlaxoSmithKline (United States) · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
681
total citations
- FWCI
- 30.66
- Percentile
- 100%
- References
- 46
Citations per year
Authors
10- MEMarcus E. RisnerCorresponding
Research Triangle Park Foundation, GlaxoSmithKline (United States)
- AMAnn M. Saunders
GlaxoSmithKline (United States), Research Triangle Park Foundation
- JFJill F.B. Altman
GlaxoSmithKline (United Kingdom)
- GCGeorge C. Ormandy
GlaxoSmithKline (United Kingdom)
- SCSuzanne Craft
University of Washington, Seattle University, University of Puget Sound, Geriatric Research Education and Clinical Center
Topics & keywords
Topics
Keywords
- Apolipoprotein E
- Placebo
- Internal medicine
- Rosiglitazone
- Population
- Medicine
- Gastroenterology
- Genotype
No related works found for this paper.